logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

The FDA Says Yes to Acadia Drug Nuplazid and More

The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) voted 12 to 2 that the benefits outweigh the risks of Acadia’s (ACAD) drug  Nuplazid™  (pimavanserin) for the treatment of psychosis associated with Parkinson’s disease. The Prescription Drug...

Read More

March 30, 2016

0

Portola Is Still a Favorite

It is an ingenuous decision made by investors who rushed to consider betrixaban Phase 3 APEX study a failure. Betrixaban is a once-daily orally administered Factor Xa inhibitor anticoagulant.  The Phase 3 AREX study was evaluating the superiority of oral betrixaban’s extended-duration anticoagulation vs....

Read More

March 24, 2016

0

Amgen: Positive Data from Osteoporosis Trial. Aerie Pharmaceuticals: More Data on Glaucoma Drug Safety.

Amgen (AMGN) and  UCB (Euronext Brussels: UCB) announced positive results from the BRIDGE pivotal Phase 3 placebo-controlled study evaluating the efficacy and safety of romosozumab in treating men with osteoporosis.   The study met the primary endpoint,  demonstrating a statistically significant increase...

Read More

March 22, 2016

0

Immunokinases Attract Roche to Blueprint Medicine. Spectrum Granted FDA Approval.

Immunotherapy for Cancer Blueprint Medicines Blueprint Medicines (BPMC)   entered into a worldwide collaboration and exclusive license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, Roche) for the discovery, development and commercialization of up to five small...

Read More

March 16, 2016

0

Celator: Improving on AML Standard of Care Treatment. The Stock Rallied.

First therapy to demonstrate statistically significant improvement in overall survival and induction response rate in a pivotal Phase 3 trial  in high-risk Acute Myeloid Leukemia (AML)   NDA submission for VYXEOS planned for later this year   Celator Pharmaceuticals (CPXX) announced...

Read More

March 15, 2016

0

Xoma: The Considered Dead is Alive and Kicking. Gilead is Way Undervalued

The Diagnosed Dead Is Far from Dying Xoma (XOMA) : Stock rallied following report announcing an upfront payment from  Novartis , which multiplied the firm’s revenues 10 times over 2014. Novartis paid Xoma $37 million, Novo Nordisk paid $5 million...

Read More

March 11, 2016

0

Jazz Pharmaceuticals: The Expected Good News on March 31, 2016

Of the Upcoming Game-Changing Actions THE EXPECTED FDA APPROVAL OF JAZZ DRUG DEFIBROTIDE On March 31,  the   FDA is expected to decide on the approval of  Jazz Pharmaceuticals’ (JAZZ)   drug  defibrotide.  The drug is for patients with hepatic...

Read More

March 10, 2016

0

Illumina: A Great Transformation and Transition

As we kept describing it,   Illumina’s (ILMN) is the engine behind the   biological revolution reflected in the current existence of treatments, which aim at targets that were unknown before this firm enabled discovering them. Illumina’s establishing and launching...

Read More

March 8, 2016

0

Immune Design: Encouraging News About Treating Allergic Diseases

Preparing a Prohost Letter dedicated to immunotherapy and the firms that are behind the promising novel approaches towards enabling the immune system to treat, or cure diseases if possible, we fell on other genius approaches. In recent Prohost Letters, we...

Read More

March 4, 2016

0

Baxalta Revolutionizes Its Pipeline with Immunotherapy Products

Baxalta (BXLT)   and Precision BioSciences a genome editing company announced a global collaboration to develop a broad series of  allogeneic chimeric antigen receptor (CAR) T  cell therapies directed towards areas of major unmet need in multiple cancers. CAR T...

Read More

February 26, 2016

0

  • Previous
  • 1
  • 2
  • 3
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy